Literature DB >> 9746073

Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection.

B Reinhardt1, R Jaspert, M Niedrig, C Kostner, J L'age-Stehr.   

Abstract

To monitor early and late events of immune system activation after primary and secondary flavivirus infection, 17 healthy persons were vaccinated with the standard 17D vaccine virus strain of yellow fever (YF). Twelve of these persons had not received YF vaccine previously and 5 had been vaccinated once at least 10 years before. Viremia and various parameters of humoral and cellular immune activation were followed daily for 7 days and weekly thereafter. Viremia was detected by reverse transcriptase-polymerase chain reaction in all 12 first-time vaccinees beginning from the second to the sixth day after vaccination; most tested positive between the fourth and sixth day. Infectious 17D virus was detected using a plaque forming assay in the serum of 7 of the 12 first-time vaccinees. As first parameters of immune activation, neopterin and beta2-microglobulin markedly increased between day 2 and day 6 postvaccination. In parallel to the viremia, circulating CD8+ T-cells significantly increased, with peak levels at day 5 after primary vaccination, indicating an activation of the cellular immune system. Neither viremia nor significant changes of these activation markers were observed in the five revaccinated persons. Neutralizing antibodies directed against the 17D vaccine strain developed in all persons within 2 weeks after vaccination. No correlation was found between the extent of viremia and the titer of neutralizing antibodies. Revaccination was followed by a minor and transient increase of neutralizing antibodies. High titers of neutralizing antibodies persisted for at least 10 years after primary vaccination.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9746073     DOI: 10.1002/(sici)1096-9071(199810)56:2<159::aid-jmv10>3.0.co;2-b

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  72 in total

1.  Virus isolation for diagnosing dengue virus infections in returning travelers.

Authors:  D Teichmann; K Göbels; M Niedrig; J-W Sim-Brandenburg; J Làge-Stehr; M P Grobusch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-10-17       Impact factor: 3.267

2.  Yellow Fever Immunizations: Indications and Risks.

Authors:  Mary E. Wilson; Lin H. Chen; Elizabeth D. Barnett
Journal:  Curr Infect Dis Rep       Date:  2004-02       Impact factor: 3.725

3.  Detection of yellow fever 17D genome in urine.

Authors:  Cristina Domingo; Sergio Yactayo; Edinam Agbenu; Maurice Demanou; Axel R Schulz; Katjana Daskalow; Matthias Niedrig
Journal:  J Clin Microbiol       Date:  2010-11-24       Impact factor: 5.948

4.  Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization?

Authors:  M A Martins; M L Silva; A P V Marciano; V Peruhype-Magalhães; S M Eloi-Santos; j G L Ribeiro; R Correa-Oliveira; A Homma; E G Kroon; A Teixeira-Carvalho; O A Martins-Filho
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

Review 5.  Systems vaccinology: learning to compute the behavior of vaccine induced immunity.

Authors:  Helder I Nakaya; Shuzhao Li; Bali Pulendran
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2011-10-19

Review 6.  Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology.

Authors:  Bali Pulendran
Journal:  Nat Rev Immunol       Date:  2009-09-18       Impact factor: 53.106

Review 7.  The yellow fever 17D virus as a platform for new live attenuated vaccines.

Authors:  Myrna C Bonaldo; Patrícia C Sequeira; Ricardo Galler
Journal:  Hum Vaccin Immunother       Date:  2014-02-19       Impact factor: 3.452

8.  Inadvertent yellow fever vaccination of a patient with Crohn's disease treated with infliximab and methotrexate.

Authors:  Christina Ekenberg; Nina Friis-Møller; Thomas Ulstrup; Claus Aalykke
Journal:  BMJ Case Rep       Date:  2016-08-29

9.  Persistence of Yellow Fever vaccine-induced antibodies after cord blood stem cell transplant.

Authors:  Vivian Iida Avelino-Silva; Marcos da Silva Freire; Vanderson Rocha; Celso Arrais Rodrigues; Yana Sarkis Novis; Ester C Sabino; Esper Georges Kallas
Journal:  Hum Vaccin Immunother       Date:  2015-11-30       Impact factor: 3.452

10.  Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses.

Authors:  Denis Gaucher; René Therrien; Nadia Kettaf; Bastian R Angermann; Geneviève Boucher; Abdelali Filali-Mouhim; Janice M Moser; Riyaz S Mehta; Donald R Drake; Erika Castro; Rama Akondy; Aline Rinfret; Bader Yassine-Diab; Elias A Said; Younes Chouikh; Mark J Cameron; Robert Clum; David Kelvin; Roland Somogyi; Larry D Greller; Robert S Balderas; Peter Wilkinson; Giuseppe Pantaleo; Jim Tartaglia; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  J Exp Med       Date:  2008-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.